Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 5 for:    OAS2

Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03540212
Recruitment Status : Recruiting
First Posted : May 30, 2018
Last Update Posted : March 15, 2019
Sponsor:
Information provided by (Responsible Party):
Manal Hamdy El-Sayed, Ain Shams University

Brief Summary:

This is an interventional Phase II/III, single center, single arm clinical trial to assess the pharmacokinetics, efficacy, safety and tolerance of daclatasvir plus sofosbuvir in treatment-naïve, non-cirrhotic adolescents with chronic HCV GT-4 infection.

A single-arm evaluation of daclatasvir/sofosbuvir will focus on the pharmacokinetics, efficacy and safety

All enrolled patients will receive daclatasvir 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily for 12 weeks.


Condition or disease Intervention/treatment Phase
Chronic HCV Infection Drug: Daclatasvir and sofosbuvir Phase 2 Phase 3

Detailed Description:

This is an interventional Phase II/III, single center, single arm clinical trial to assess the pharmacokinetics efficacy, safety, and tolerance of daclatasvir plus sofosbuvir in treatment-naïve, non-cirrhotic adolescents with chronic HCV GT-4 infection.

A single-arm evaluation of daclatasvir/sofosbuvir will focus on the efficacy, safety and pharmacokinetics, confirm the favorable pharmacological profile.

All enrolled patients will receive daclatasvir 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily for 12 weeks.

Patients will be followed closely for disease progression and any hypersensitivity or adverse reactions due to therapy. Laboratory values to be monitored at baseline: Serum creatinine, bilirubin, AST, ALT, HCV viral load (VL).

Fifty patients will be included; the first twenty patients will be candidates for pharmacokinetic assessment. All patients (50), will be candidates for safety and efficacy assessment after verifying the PK results ''phase II''. Patients will be recruited at Ain Shams University hospitals, Egypt. The study will be conducted after approval of the corresponding research ethical committee and obtaining an informed consent from the parents/guardians and an assent from the patients.

Patients will be requested to come for 2 screening visits, at the first day of therapy, weekly during the first four weeks, at the end of week 8 and week 12. Patients who will complete their treatment schedule will be scheduled for a visit after 12 weeks from end of therapy for assessment of sustained virological response (SVR). The total number of visits are 9. Duration of follow up will be 24 weeks from treatment initiation in addition to the screening period (2-4 weeks).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Pharmacokinetics, Safety and Efficacy Study of Daclatasvir/Sofosbuvir in Adolescents Aged 12 to 18 Years Old With Hepatitis C Virus: A Preliminary Study
Actual Study Start Date : December 10, 2017
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Daclatasvir and sofosbuvir

Daclatasvir and sofosbuvir

Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks

Drug: Daclatasvir and sofosbuvir

Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.

DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.

DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.

Other Names:
  • DCV-SOF
  • Sofosbuvir-Daclatasvir




Primary Outcome Measures :
  1. Measurement of the pharmacokinetics of DCV-SOF [ Time Frame: Blood samples will be collected on day 8 of therapy ]

    Blood samples (3 mL) will be collected to measure dactalasvir concentrations from pediatric patients using a nine-point plasma schedule (pre-dose, 0.5,1, 2, 4, 8, 12, and 24 h post-dose) on day 8 of therapy.

    (This will be a total of 27 mL/patient, which is well below the maximum allowed internationally recognized value of blood loss is 2.4mL/kg in a 4 month period. Any deviations from nominal sampling times should be recorded.

    AUCtau which is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval will be calculated



Secondary Outcome Measures :
  1. Measurement of Number of Participants With sustained virological response (SVR12), 12 weeks after discontinuation of therapy with daclatasvir-sofosbuvir (DCV-SOF). [ Time Frame: 12 weeks after discontinuation of therapy with daclatasvir-sofosbuvir (DCV-SOF). ]
    Number of Participants With sustained virological response at 12 Weeks after end of study drug treatment (SVR12) will be recorded, participant will be considered to have achieved SVR12 if HCV RNA is less than the lower limit of quantification of <15 IU/ml) at 12 weeks after the end of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adolescents (ages 12- 18 years) and/ or weight ≥ 35 kg
  2. HCV genotype 4 infected
  3. Naïve non-cirrhotic population with FIB Score: F0 to F3.
  4. Screening laboratory values within define thresholds
  5. Both sex
  6. Evidence of HCV infection determined by positive anti-HCV antibody and HCV RNA by polymerase chain reaction (PCR)
  7. HCV treatment-naïve
  8. Absolute neutrophil count ≥ 1,500/mm3
  9. Hemoglobin level ≥ 10 g/dL
  10. Platelets > 75000 cells/mm3
  11. Albumin > 3.5 mg/dL
  12. PT < 3 sec above control and INR within accepted range
  13. Random glucose level within normal range
  14. Serum creatinine < 1.5 mg/dL
  15. Biopsy is not required for study entry.
  16. Signing informed consent by parents and patient assent

Exclusion Criteria:

  1. Previous treatment for HCV.
  2. History of clinically significant illness or any other medical condition that may interfere with individuals' treatment, assessment, or compliance with protocol.
  3. Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus
  4. Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage)
  5. Pregnant or nursing females
  6. Use of any illicit concomitant medications as within 28 days of the Day 1
  7. Renal dysfunction
  8. Ongoing treatment with Prohibited drugs.
  9. Chronic liver disease due to a cause other than HCV e.g. autoimmune disease, Wilson disease,…etc.
  10. Alfa-fetoprotein level >50 ng/mL
  11. Serum creatinine >1.5 mg/dL
  12. Simultaneous acute hepatitis A infection
  13. Known hypersensitivity to daclatasvir or sofosbuvir
  14. History of gastrointestinal disease or surgical procedure
  15. Blood /blood product transfusion within 4 weeks prior to study
  16. Systemic corticosteroid use for more than 2 weeks (pulmonary/nasal administration was permitted)
  17. Psychiatric hospitalization, suicide attempt or disability resulting from psychiatric illness within the prior 5 years
  18. Clinically relevant alcohol or drug abuse within 12 months of screening
  19. Ongoing treatment with any medications interacting with daclatasvir/sofosbuvir

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03540212


Contacts
Layout table for location contacts
Contact: Manal H El-Sayed, MD 00201227461120 manalhelsayed@yahoo.co.uk
Contact: Fatma SE Ebeid, MD 00201095569596 dr.fatma_ebeid@yahoo.com

Locations
Layout table for location information
Egypt
Pediatric Department, Faculty of Medicine, Ain Shams University Recruiting
Cairo, Non-US, Egypt, 11556
Contact: Manal H El-Sayed, MD    00201227461120    mamalhelsayed@yahoo.co.uk   
Contact: Fatma Soliman E Ebeid, MD    1095569596 ext Ebeid    dr.fatma_ebeid@yahoo.com   
Principal Investigator: Manal H El-Sayed, MD         
Sub-Investigator: Fatma SE Ebeid, MD         
Sub-Investigator: Aya M Kamal, MD         
Sub-Investigator: Mohamed Hassany, MD         
Sub-Investigator: Mogeb M Saif, MD         
Sub-Investigator: Samar F Farid         
Sub-Investigator: Maggie M Abbassi         
Sub-Investigator: Sara Makkeyah, MD         
Sub-Investigator: Mary Akhnokh, MD         
Sponsors and Collaborators
Ain Shams University
Investigators
Layout table for investigator information
Principal Investigator: Manal H El-Sayed, MD Professor of Pediatric, Faculty of Medicine, Ain Shams University, Egypt

Layout table for additonal information
Responsible Party: Manal Hamdy El-Sayed, Professor of Pediatrics, Ain Shams University
ClinicalTrials.gov Identifier: NCT03540212     History of Changes
Other Study ID Numbers: FMASU P69a/2017
First Posted: May 30, 2018    Key Record Dates
Last Update Posted: March 15, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis C
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Sofosbuvir
Antiviral Agents
Anti-Infective Agents